Uridine Binding and Transportability Determinants of Human Concentrative Nucleoside Transporters
Authors:
- Kyla M. SmithKSKyla M. Smith
- Tracey TackaberryTTTracey Tackaberry
- Frank VisserFVFrank Visser
- Morris J. RobinsMRMorris J. Robins
- Lars P. C. NielsenLNLars P. C. Nielsen
- Ireneusz NowakINIreneusz Nowak
- Edward KarpinskiEKEdward Karpinski
- Stephen A BaldwinSBStephen A Baldwin
- James D. YoungJYJames D. Young
- Carol E CassCCCarol E Cass
Open Access
- 1 September 2005
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 68 (3) , 830-839
Abstract
Human concentrative nucleoside transporters 1, 2, and 3 (hCNT1, hCNT2, and hCNT3) exhibit different functional characteristics, and a better understanding of their permeant selectivities is critical for development of nucleoside analog drugs with optimal pharmacokinetic properties. In this study, the sensitivity of a high-throughput yeast expression system used previously for hCNT1 and hCNT3 was improved and used to characterize determinants for interaction of uridine (Urd) with hCNT2. The observed changes of binding energy between hCNT2 and different Urd analogs suggested that it interacts with C(3′)-OH, C(5′)-OH, and N(3)-H of Urd. The C(2′) and C(5) regions of Urd played minor but significant roles for Urd-hCNT2 binding, possibly through Van der Waals interactions. Because the yeast assay only provided information about potential transportability, the permeant selectivities of recombinant hCNT1, hCNT2, and hCNT3 produced in Xenopus laevis oocytes were investigated using a two-electrode voltage clamp assay. hCNT1-mediated transport was sensitive to modifications of the N(3), C(3′), and C(5′) positions of Urd. hCNT2 showed some tolerance for transporting Urd analogs with C(2′) or C(5) modifications, little tolerance for N(3) modifications, and no tolerance for any modifications at C(3′) or C(5′) of Urd. Although hCNT3 was sensitive to C(3′) modifications, it transported a broad range of variously substituted Urd analogs. The transportability profiles identified in this study, which reflected the binding profiles well, should prove useful in the development of anticancer and antiviral therapies with nucleoside drugs that are permeants of members of the hCNT protein family.Keywords
This publication has 24 references indexed in Scilit:
- Electrophysiological characterization of a recombinant human Na+‐coupled nucleoside transporter (hCNT1) produced in Xenopus oocytesThe Journal of Physiology, 2004
- Interactions of Nucleoside Analogs, Caffeine, and Nicotine with Human Concentrative Nucleoside Transporters 1 and 2 Stably Produced in a Transport-Defective Human Cell LineMolecular Pharmacology, 2004
- Molecular Requirements of the Human Nucleoside Transporters hCNT1, hCNT2, and hENT1Molecular Pharmacology, 2004
- Molecular Identification and Characterization of Novel Human and Mouse Concentrative Na+-Nucleoside Cotransporter Proteins (hCNT3 and mCNT3) Broadly Selective for Purine and Pyrimidine Nucleosides (System cib)Journal of Biological Chemistry, 2001
- Structure-inhibitory profiles of nucleosides for the human intestinal N1 and N2 Na + -nucleoside transportersCancer Chemotherapy and Pharmacology, 2000
- Nucleoside transporters: molecular biology and implications for therapeutic developmentMolecular Medicine Today, 1999
- Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridineMolecular Membrane Biology, 1998
- Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1)American Journal of Physiology-Cell Physiology, 1997
- A series of yeast/Escherichia coli λ expression vectors designed for directional cloning of cDNAs and cre/lox‐mediated plasmid excisionYeast, 1993
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973